Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02796001 · ClinicalTrials.gov registry record · Phase 1
Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans
A Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT02796001 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 46 participants.
The verdict
NCT02796001, a Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the relationship between rhinovirus specific T-cell immunity and the human host response to primary rhinovirus challenge and subsequent secondary challenge with either homologous or heterologous rhinovirus serotypes.
Interventions
- OTHER no intervention
- BIOLOGICAL human rhinovirus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2020-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02796001
The ClinicalTrials.gov registry entry for NCT02796001 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which no intervention is the first listed.
NCT02796001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02796001 about?
NCT02796001 is a clinical study titled "Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans". The primary objective of this study is to assess the relationship between rhinovirus specific T-cell immunity and the human host response to primary rhinovirus challenge and subsequent secondary challenge with either homologous or heterologous rhinovirus serotypes.
What is the current status of trial NCT02796001?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2017-09-25. Estimated completion is 2020-05-01.
What interventions are being tested in trial NCT02796001?
The interventions under investigation include: no intervention (OTHER), human rhinovirus (BIOLOGICAL).
Who is sponsoring clinical trial NCT02796001?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.